STEK Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -95.33% compared to Stemtech Corp.'s net margin of -135.28%. Stemtech Corp.'s return on equity of -- beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Stemtech Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.35 which suggests that it could grow by 239.43%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Stemtech Corp., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Stemtech Corp..

Stemtech Corp. has a beta of 2.950, which suggesting that the stock is 194.98% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Stemtech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stemtech Corp. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Stemtech Corp. quarterly revenues are $852.3K, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Stemtech Corp.'s net income of -$812.5K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Stemtech Corp.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stemtech Corp. is 0.04x versus 3.26x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of -95.33% compared to Stemtech Corp.'s net margin of -361.39%. Stemtech Corp.'s return on equity of -- beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

Stemtech Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 106.67%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Stemtech Corp., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Stemtech Corp..

Stemtech Corp. has a beta of 2.950, which suggesting that the stock is 194.98% more volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

Stemtech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stemtech Corp. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Stemtech Corp. quarterly revenues are $852.3K, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Stemtech Corp.'s net income of -$812.5K is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Stemtech Corp.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stemtech Corp. is 0.04x versus 52.04x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -95.33% compared to Stemtech Corp.'s net margin of 15.59%. Stemtech Corp.'s return on equity of -- beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Stemtech Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.6429 which suggests that it could grow by 20.72%. Given that Travere Therapeutics, Inc. has higher upside potential than Stemtech Corp., analysts believe Travere Therapeutics, Inc. is more attractive than Stemtech Corp..

Stemtech Corp. has a beta of 2.950, which suggesting that the stock is 194.98% more volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Stemtech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stemtech Corp. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Stemtech Corp. quarterly revenues are $852.3K, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Stemtech Corp.'s net income of -$812.5K is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Stemtech Corp.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stemtech Corp. is 0.04x versus 7.18x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -95.33% compared to Stemtech Corp.'s net margin of -49.65%. Stemtech Corp.'s return on equity of -- beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Stemtech Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1841.75%. Given that Xenetic Biosciences, Inc. has higher upside potential than Stemtech Corp., analysts believe Xenetic Biosciences, Inc. is more attractive than Stemtech Corp..

Stemtech Corp. has a beta of 2.950, which suggesting that the stock is 194.98% more volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Stemtech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stemtech Corp. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Stemtech Corp. quarterly revenues are $852.3K, which are smaller than Xenetic Biosciences, Inc. quarterly revenues of $1M. Stemtech Corp.'s net income of -$812.5K is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Stemtech Corp.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stemtech Corp. is 0.04x versus 1.11x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.